ImmunityBio shares jumped 3% on Monday after filing a detailed response to FDA promotional compliance concerns raised on March 13, 2026.
The company clarified the TV ad was never aired, removed a podcast from its site, and requested third‑party takedown.
CEO Richard Adcock announced mandatory executive training, expanded review committee protocols, and external counsel audit to strengthen advertising compliance.
Founder Dr Patrick Soon‑Shiong’s podcast remarks were framed as aspirational pipeline commentary, and ANKTIVA’s bladder‑cancer indication was reiterated.